MDWD Key Statistics, Chart & Performance
The current stock price of MDWD is 17.06 USD. In the past month the price decreased by -7.48%. In the past year, price increased by 3.52%.
MDWD Latest News, Press Relases and Analysis
MDWD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.14B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.04B |
Related stock screener links
About MDWD
Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 111
Phone: 972779714100
MEDIWOUND LTD / MDWD FAQ
What does MDWD do?
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
What is the stock price of MEDIWOUND LTD today?
The current stock price of MDWD is 17.06 USD. The price increased by 1.19% in the last trading session.
Does MEDIWOUND LTD pay dividends?
MDWD does not pay a dividend.
How is the ChartMill rating for MEDIWOUND LTD?
MDWD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MDWD stock?
MDWD stock is listed on the Nasdaq exchange.
What sector and industry does MEDIWOUND LTD belong to?
MEDIWOUND LTD (MDWD) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the number of employees for MEDIWOUND LTD?
MEDIWOUND LTD (MDWD) currently has 111 employees.
MDWD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD turns out to be only a medium performer in the overall market: it outperformed 51.4% of all stocks.
MDWD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. MDWD has a bad profitability rating. Also its financial health evaluation is rather negative.
MDWD Financial Highlights
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 34.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.72% | ||
| ROE | -138.93% | ||
| Debt/Equity | 0.4 |
MDWD Forecast & Estimates
12 analysts have analysed MDWD and the average price target is 31.28 USD. This implies a price increase of 83.35% is expected in the next year compared to the current price of 17.06.
For the next year, analysts expect an EPS growth of 8.58% and a revenue growth 19.48% for MDWD